Mission Therapeutics to Attend and Present at Bio€quity Europe Digital 2021

CAMBRIDGE, UK– 14 May 2021Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced that management team members will be attending and presenting at Bio€quity Europe (17-19 May).

Anker Lundemose, CEO, David Luther, CFO, and Paul Wallace, CBO, will attend the digital event and will be available for partnering meetings. Mission’s corporate presentation is available to all delegates via the partneringONE digital event platform.

In addition, Anker will present on 19 May at 10:00 CET as part of the 10th CEO Workshop: Hiring and Team Building in the Age of COVID. The workshop will explore how best practices for hiring A-list talent have evolved during the pandemic, including what is expected to be the long-term impact. The panel will also discuss how they have kept their teams motivated and productive over the past year.

Bio€quity Europe Digital is an international networking platform that enables financial dealmakers and biopharma executives to meet rising biotechs. Industry leaders will debate the big questions framing the future of biopharma innovation and identify where Europe will continue to be a global leader. The three-day virtual event will include strategic panels focused on ‘Europe’s Next Act’ and will support one-to-one virtual meetings, with over 130 corporate presentations available from European and Asian biotechs.

– ENDS –

FOR MORE INFORMATION:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340

Instinctif Partners
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013
missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.

To date the Company has received £73 million /$101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.